Zevra Therapeutics (NASDAQ: ZVRA) recently received a number of ratings updates from brokerages and research firms:
- 8/7/2026 – Zevra Therapeutics had its price target lowered by Guggenheim from $24.00 to $23.00. They now have a “buy” rating on the stock.
- 8/6/2026 – Zevra Therapeutics had its “outperform” rating reaffirmed by Citigroup Inc..
- 8/6/2026 – Zevra Therapeutics had its price target raised by Citizens Jmp from $25.00 to $28.00. They now have a “market outperform” rating on the stock.
- 7/27/2026 – Zevra Therapeutics had its price target lowered by Guggenheim from $29.00 to $24.00. They now have a “buy” rating on the stock.
- 7/27/2026 – Zevra Therapeutics had its price target lowered by Canaccord Genuity Group Inc. from $29.00 to $20.00. They now have a “buy” rating on the stock.
- 7/27/2026 – Zevra Therapeutics had its price target lowered by BTIG Research from $27.00 to $24.00. They now have a “buy” rating on the stock.
- 7/12/2026 – Zevra Therapeutics was upgraded by Wall Street Zen from “hold” to “buy”.
- 6/24/2026 – Zevra Therapeutics had its “buy” rating reaffirmed by UBS Group AG.
- 6/23/2026 – Zevra Therapeutics had its “buy” rating reaffirmed by HC Wainwright. They now have a $26.00 price target on the stock.
Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome.
Featured Stories
- Five stocks we like better than Zevra Therapeutics
- Atlassian Just Pulled Off the Software Comeback Wall Street Wanted
- AST SpaceMobile Earnings Just Reminded Investors How Risky Space Can Be
- NVIDIA’s Rally Sets Up a Bigger Test Ahead of Earnings
- Apple’s Next iPhone Could Test How Much Pricing Power Is Left
Receive News & Ratings for Zevra Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zevra Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.
